Pharma IQ's Predictive Toxicology Conference to Feature Industry Panel on Reducing Risks Associated with New Predictive Toxicology Technology

Top Quote Drug Safety Executive Council Moderates Panel. End Quote
  • (1888PressRelease) January 25, 2011 - London, UK - Pharma IQ, a division of IQPC, a leading organiser of conferences worldwide, announced today that the Drug Safety Executive Council (DSEC) will lead an expert panel, "Reducing Risks Associated with New Predictive Toxicology Technology, "during Pharma IQ's Predictive Toxicology conference, on February 22 - 24, 2011 at the America Square Conference Centre, London, UK.

    The conference is focused on striving to reduce late-stage drug attrition through predictive toxicology approaches in drug safety, thereby helping to maximise drug candidate success and profitability.

    On Wednesday, 23rd February, DSEC will lead an industry panel on "Reducing the Risks Associated with the Adoption of Novel Technologies." The panel will be moderated by Dr. Ernie Bush, Vice President, Collaborative Projects at DSEC and will include experts from AstraZeneca, Bayer Healthcare and UCB Pharma.

    The panel will address the following questions:

    -Do you see the role of in vitro toxicity assays increasing in importance and frequency prior to animal toxicity testing? What in vitro assays are most often used now (other than ADME) prior to animal toxicity testing?

    -Would you only implement a technology that you would run in-house?

    -How does potential regulatory acceptance factor into a decision to adopt a new technology (--or-- does good science triumph over regulatory uncertainty)?

    -To what extent are stem cells being used for in vitro cell-based assays to identify drugs with higher efficacy and minimal toxicity? What are the barriers that must be overcome for this approach to accelerate progress?

    -To what extent do you need to qualify or validate a novel technology so that your project team will accept it?

    -At what level of management is the decision taken to evaluate and adopt a new technology?

    For more information on how you can attend this session please visit:

  • FB Icon Twitter Icon In-Icon
Contact Information